Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria. A placebo-controlled study
DOI:
https://doi.org/10.2340/0001555568541544Abstract
Ten patients with cholinergic urticaria (CU) were entered into a double-blind, placebo-controlled, cross-over study. They were scheduled to receive acrivastine 8 mg t.d.s., hydroxyzine hydrochloride 20 mg t.d.s. and placebo according to a fully randomized, balanced treatment plan. Subjective clinical assessments and objective measurements following exercise challenge were performed during the study period. Both acrivastine and hydroxyzine were shown to be effective and well tolerated in the treatment of cholinergic urticaria. In addition, a trend was demonstrated for both active agents to improve peak expiratory flow rate (PEFR) following exercise, when compared with placebo, and this trend reached statistical significance in the case of acrivastine (p less than 0.05).Downloads
Download data is not yet available.
Downloads
Published
1988-11-01
How to Cite
Kobza, B., Aboobaker, J., Gibson, J., Harvey, S., & Marks, P. (1988). Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria. A placebo-controlled study. Acta Dermato-Venereologica, 68(6), 541–544. https://doi.org/10.2340/0001555568541544
Issue
Section
Articles
License
LicenseAll digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
